Introduction
Hypertension (elevated blood pressure levels exceeding 140/90 mmHg according to WHO criteria) is a common complex disorder, which affects 15-20% of adult population in Western societies. 1 It is classified as primary (essential) or secondary hypertension. The former type is used to describe hypertension without a known pathology. The diagnosis of essential hypertension is made when no other cause for increased blood pressure is found. This form of the disease constitutes about 90-95% of all hypertension cases; whereas in 5% of cases, the cause of hypertension is known to be secondary to conditions such as pheochromocytoma, primary hyperaldosteronism (Conn's syndrome), Cushing's syndrome (excessive glucocorticoids), renal diseases or drug induced. The disease is considered to be a multifactorial disorder with many genetic, environmental and demographic factors contributing to blood pressure variation. The complex nature of the involved regulatory mechanisms makes it difficult to identify a single pathological system of prime importance in regulating blood pressure.
Hypertension is one of the most important risk factors for cardiovascular diseases. It is one of the principal independent risk factors for stroke, myocardial infarction and end-stage renal disease. 1 Furthermore, it is associated with many other complications that affect vital body functions such as left ventricular hypertrophy, diastolic dysfunction, congestive heart failure, cerebral thrombosis/ haemorrhage, hypertensive encephalopathy, microalbuminuria, carotid artery stiffening, arterial aneurysms and dissections and retinopathy.
It is estimated that the genetic element contribution to blood pressure variation ranges from 30 to 50%. Identifying gene variants that contribute to hypertension may not only provide better understanding of the pathophysiology of the disease but also may elucidate the biochemical and physiological pathways that link various risk factors in hypertension. Furthermore, it will also help understanding the interaction between genes and environmental factors. Discovering hypertension susceptibility genes would help recognizing those at risk for developing the disease before the manifestation of clinical symptoms. This may lead to new therapeutic approaches, and shift the focus of management towards prevention rather than treatment. In addition, the genetic approach could help tailoring drug therapy in hypertension so that the existing drugs are used in a more directed way to treat individuals with specific genotypes.
This review attempts to summarize present known genetic variations that may be implicated in the pathogenesis of hypertension and to discuss various research strategies used to identify them. It also highlights some of the opportunities and challenges, which may arise in interpreting the value of these genetic variations to improve the management of hypertension.
Search strategy
Initially, we performed a broad literature search limited to articles published in English using PubMed Database. The key words used were 'hypertension' and 'genetics'. The search was expanded by including references appeared under the 'related articles' link in numerous citations appeared in the primary search. These additional references were mostly reviews or studies dedicated to a specific genetic variation, condition or methodology. Furthermore, we had our own considerable collection of full articles collected over the past years (these were obtained in collaboration with Professor R Bayoumi who is the principal investigator of leading research project on genetics of hypertension in Oman; MT is the pharmacogenomics coinvestigator in this project). Abstracts of all references and full-text of those articles that had merit to the main aim of the review, that is, appraising the correlation between genetic variations and hypertension pathogenesis, were obtained. The search emphasis was directed to articles published in the past 10 years. All gathered information in the form of abstract or full article were reviewed, assessed and categorized as per the subheadings of the review.
Genetics of hypertension
Genetic epidemiological studies have suggested that several genetic variants increase the risk for hypertension. 2 It is likely that a number of genes rather than a single gene account for the heritability of this complex disorder. However, the genetic analysis of hypertension produced complex, inconsistent and nonreproducible results, which makes it difficult to draw conclusions about the association between specific genes and hypertension. 3 
Current research strategies
In search for hypertension-predisposing genetic loci (hypertension susceptibility genes), several strategies have been used. 4 These include:
(1) candidate gene approach; (2) genome-wide scan (GWS); 
Candidate gene approach
Most genetic studies of hypertension-predisposing genetic loci have used this strategy to study candidate genes. This systematic approach assumes that a gene or a set of genes involving a specific physiological or cellular function contribute to blood pressure variation. Utilizing this approach, some candidate genes have been elucidated from the study of rare monogenic forms of hypertension such as Liddle's syndrome (see below). For essential hypertension, however, at least 51 genes/loci that affect different physiological and biochemical systems have been described. Most of the studies utilized genetic linkage and association methods and enrolled unrelated individuals in case-control designs. Although case-control design is useful in homogenous populations, these studies were performed in heterogeneous populations and thus may have higher probability of both type 1 and type 2 errors. 4 Case-control design also renders candidate gene studies less likely to be reproducible and less expected to include all causative genes and polymorphisms. 5 This issue is further discussed in the Conclusion section.
Genome-wide scanning
In this approach, hundreds of polymorphic markers are genotyped, preferably evenly distributed through the genome in a selected sample of individuals with or without a qualitative trait or with a measurable quantitative trait. This approach has the advantage of testing all genomic regions. Therefore, it is not biased by previous hypotheses of molecular pathogenesis. GWS studies identified linkage to different chromosomal regions. For example, Krushkal et al 6 identified four regions of the genome; viz. 2q22.1-2p21, 5q33.3-5q34, 6q23.1-6q24.1, 15q25.1-15q26.1, linked to SBP. Sharma et al 7 identified a sibling-pair linkage to hypertension at a locus on chromosome 11q. Also, quantitative trait loci (QTLs) on chromosome 2 have been shown by a recent study that suggested the SLC4A5 gene as a candidate for hypertension. 8 Other suggestive linkages were found in a study of sibling pairs selected on the basis of blood pressure extremes in Chinese population. 9 Levy et al 10 selected participants from two generations of the Framingham Heart Study and found a strong evidence for a blood pressure QTL on chromosome 17. Additionally, quantitative trait linkage analysis in the Old Order Amish population found a strong association to both diastolic and to a lesser extent systolic blood pressure in the region of chromosome 2q31-34. 11 The single largest GWS study was the British Genetics of Hypertension study (BRIGHT) that was published recently. 12 This study implied that essential hypertension has an oligogenic element and found a principal locus on chromosome 6q. The study population included severely affected sibling pairs who had early-onset hypertension which might help in identifying families with strong genetic influences for hypertension. Similar strong evidence has been gathered on a locus on chromosome 2p11 at marker D2S1790 which was reproduced in at least three genomewide linkage studies. [13] [14] [15] However, some GWS studies failed to find a linkage with essential hypertension. Ranade et al 16 found no significant evidence of linkage to a single locus in the genome in populations of Chinese and Japanese origins. Furthermore, a meta-analysis of genome-wide linkage scans of the US Family Blood Pressure programme failed to achieve genome-wide significance. 17 This suggests that large numbers of individuals in a study might not be sufficient in the presence of ethnic and phenotypic heterogeneity.
Intermediate phenotype approach
Intermediate phenotypes are characteristics that have greater habitability than the trait itself. They represent an early stage towards the development of hypertension and may aid in the search for hypertension susceptibility genes. As an example, Williams et al 18 described a phenotype called 'nonmodulation', which is characterized by inability to modulate aldosterone secretion and renal blood flow by angiotensin II in a subset of essential hypertensive patients. Recent studies suggested an association of this phenotype with M235T genotype at the angiotensinogen locus. 19 Another example of intermediate phenotypes is the increased urinary free cortisol concentration that is associated with salt-sensitive hypertension. 20 Comparative genomics This approach employs data from animal studies to target potential blood pressure loci in humans. Results indicated that genes on human chromosome 17 are involved in essential hypertension. Julier et al 21 investigated a region on human chromosome 17, which is homologous to blood pressure loci on rat chromosome 10. They found two closely linked microsatellite markers, D17S183 and D17S934, that were significantly associated with essential hypertension. These markers were close to the ACE locus in the homology region. Two subsequent studies also found linkage to microsatellite markers on chromosome 17. 22, 23 However, the largest study performed to date showed no significant linkage of essential hypertension to chromosome 17.
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A recent study presented a comparative genomic map for candidate hypertensive loci in humans based on the translation of QTLs between rats and humans. 25 This study predicted 26 chromosomal regions in the human genome that are very likely to contain hypertension genes.
Methods used to identify candidate genes in hypertension
The most straightforward method to search for genes predisposing to a complex trait is to sequence a specific gene from several affected individuals and look for variants associated with the disease. However, this approach has its restrictions due to the large number of genes and the limitations of current sequencing methods. Currently, the most widely used methodologies for this purpose have been categorized into four groups. 26 
Linkage analysis
This method gives estimates for the genetic parameters behind any trait/s being studied and proposes a model to explain the inheritance pattern of phenotypes and genotypes observed in a pedigree. 26 It provides information on gene frequency, mode of inheritance, penetrance and phenocopies.
Allele-sharing methods
These methods differ from linkage analysis in being nonparametric methods. This means that they assume no model for the inheritance of the trait. They are statistical modelling alternations to linkage analysis and they rely on relatives sharing a different proportion of alleles.
Association analyses
Association analyses are performed by comparing cases and controls for differences in presumed risk factors, like alleles. These studies are more effective than linkage analysis in studying hypertension genetics because they have greater statistical power to detect several genes for small effect. 5 Studies using animal models These are useful in providing new biological insights into a given phenotype.
Takahashi and Smithies 27 reviewed gene-targeting approaches and classified them into either analytical or synthetic. The former aims at demonstrating a correlation between specific gene variants and hypertension. This is usually achieved by identifying candidate genes by looking at the segregation patterns of genetic markers and blood pressure, or looking directly for gene variations that correlate with a specific phenotype, for example, renin gene variation. 28 On the other hand, in synthetic experiments, the effect of gene expression on a specific phenotype (blood pressure in this case) is studied. An example of synthetic approaches is the use of 'knockout animals.' Experiments using the synthetic approach rely on previous data collected by analytical experiments. The authors 27 claim that use of the synthetic approach provides evidence of genetic causation, which cannot be proved by the analytical method.
Gene titration method is one of the synthetic approaches. In this method, the effect of varying the expression of a selected gene on a particular phenotype is studied. Based on gene titration experiments, genes affecting blood pressure can be classified into three groups: 27 1. Gene/s whose level of expression directly lead to changes in blood pressure such as Natriuretic Peptide Receptor 1 gene. 2. Gene/s whose level of expression does not alter blood pressure unless another environmental factor is changed such as the effect of Atrial Natriuretic Peptide gene. This gene expression leads to hypertension if only associated with increased intake of dietary salt. 3. Gene/s whose level of expression has no affect on blood pressure but are needed to maintain normal blood pressure such as Angiotensin Converting Enzyme (ACE) gene.
Findings of studies on genetics of hypertension

Mendelian (monogenic) forms of hypertension
A lot of information obtained in the field of hypertension genetics came from single-gene disorders from which gene variants causing the trait were characterized. Liddles's syndrome Liddle's syndrome is an autosomal dominant disorder that leads to increased resorption of sodium and water in the renal collecting tubules and hence leads to hypertension. The syndrome was found to be due to mutations in the genes coding for the b and g subunits of ENaC (epithelial sodium channel).
29,30
Syndrome of apparent mineralocortecoid excess (AME) AME is an autosomal recessive disorder characterized by early onset of moderate to severe hypertension. Patients with AME1 have a deficit in 11b-hydroxysteroid dehydrogenase (11b-HSD) that leads to inactivation of cortisol, 31 while patients with AME2 have reduced function of the enzyme because of different mutation in the same gene.
Glucocorticoid-remediable aldosteronism (GRA)
GRA is an autosomal dominant trait caused by a gene duplication arising from unequal crossover between the genes encoding for aldosterone synthase and 11b-hydroxylase. 32 As a result, high amounts of aldosterone, which is under the control of adrenocorticotropic hormone, will be secreted leading to increased salt and water re-absorption and rise in blood pressure.
Mineralocorticoid receptor (MR) activating mutation
Substitution of leucine for serine at codon 810 (S810L) mutation in the mineralocorticoid receptor causes early-onset hypertension that is markedly exacerbated in pregnancy. This mutation results in constitutive MR activity and alters receptor specificity. 33 All steroids, including progesterone, that display antagonist properties when bound to the wild-type MR are able to activate the mutant receptor (L810).
Pseudohypoaldosteronism type II
Pseudohypoaldosteronism type II is an autosomal dominant disease characterized by severe hypertension, hyperkalemia and sensitivity to thiazide diuretics. 34 This results from altering Na-Cl and K þ handling. Mutations in two members of the WNK kinase family, WNK1 and WNK4, cause the disease. 35 Both genes are highly expressed in the kidney.
The above-mentioned forms of hypertension affect a common pathway viz. the regulation of salt reabsorption in the kidney, which indicates a key role of the kidney in the pathophysiology of hypertension. Extensive data from experimental animals suggest that hypertension cannot be sustained without active participation of the kidney. 36 In addition, marked elevation of blood pressure in response to increased dietary salt intake has been observed in humans, 37 primates 38 and rodents, 39 indicating the importance of inherited variation in renal salt handling. The relation between genetic variation and monogenic forms of hypertension provides insight into more the common form of hypertension especially in patients where the genetic defect has been characterized. For example, it was suggested that the T594M mutation of ENaC associates with hypertension in Black patients, 40 and that polymorphisms in aldosterone synthase associate with essential hypertension.
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Essential (polygeneic) form of hypertension
Renin-angiotensin-aldosterone (RAA) system (Table 1) The RAA system is one of the most extensively studied systems in relation to genetic susceptibility to hypertension. Several components of this system have been investigated. Among these, the angiotensinogen (AGT) gene relatively produced more consistent positive findings so far. Sib-pair linkage analysis of this gene showed that molecular variants of AGT predispose to hypertension. 42 A recent metaanalysis review showed an association between methionine-to-threonine substitution at position 235 (M235T) with an increased risk of hypertension. 43 It was suggested that this allele has a different role among different ethnic groups, with positive association for White individuals but not for Blacks or Asians. 44 However, in a study performed among Australian Anglo-Celtic Caucasians, AGT gene was not considered as a contributor to the aetiology of hypertension. 45 A linkage analysis study using the affected-pedigree-member method found a linkage between AGT locus and hypertension, but no association to M235 T was found. 46 ACE gene was also implicated in the aetiology of hypertension. Most studies showed no association or linkage between ACE gene and hypertension. [47] [48] [49] However, this gene-coding area carries an insertion/ deletion (I/D) polymorphism within intron 16. Some studies showed that this polymorphism affects blood pressure more in male than in female subjects. 49, 50 Recent quantitative analysis in a large population-based sample of men and women found genetic linkage between the ACE locus and high blood pressure in men, although the effect was found to be weak. 51 It was suggested that the D allele of ACE gene might be a risk factor for hypertensive type II diabetes.
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A cross-sectional case-control study in Caucasians found that the A1166C variant of angiotensin receptor type I gene (AT 1 ) was associated with hypertensive individuals who have a positive family history. 53 However, results from different populations are controversial. Some studies showed an association, [54] [55] [56] whereas others found none. 57 A recent study showed that this polymorphism could account for excess hypertension in African Americans. 58 In one study, blood pressure values were lower in individuals carrying the homozygous CC genotype of this gene. 59 A minor QTL was found near the AT 1 locus in a rat model of hypertension. 60 The T344C allele variant of aldosterone synthase gene (CYP11B2) may be a genetic marker for low renin hypertension. 61 One study reported a higher percentage of hypertensives with the T allele (60%) compared to normotensives. 62 Studies in Japanese population did not provide consistent results. One study found an association between CYP11B2 gene and low-renin hypertension. 63 This finding was not duplicated in another large population-based study. 64 A strong association between the intron 2 conversion allele of this gene and essential hypertension was found in the White population. 65 A haplotype analysis showed that the T-344C and A6547G, but not the T4986C, variants of this gene are associated with hypertension in females of the Anglo-Celtic population. 66 Other gene studies in the RAA system include renin gene, 67 renin binding protein genes 68 and tissue kallikrein gene promoter (KLK1). 69 G-proteins/signal transduction pathway system (Table 2 ) These signalling pathways are influenced by hormones and neurotransmitters and act to regulate blood pressure. For example, the regulator of G protein signalling (RGS2) has selectivity for the Gaq subclass of G-proteins, which are coupled to many cardiovascular hormones such as angiotensin II, endothelin I, thromboxane A and norepinephrine. 70 Polymorphisms in gene coding for G-protein subunits are expected to have a significant effect on the cardiovascular system. Hence, studying the genetic polymorphisms of the components of this system might give a new insight into the genetics of hypertension and may suggest novel downstream targets for therapy.
Polymorphism in the b 3 subunit of G-protein gene (GNB3) was perceived as an excellent candidate to study cardiovascular pharmacogenetics. 71 GNB3 contains a novel polymorphism (C825T) associated with a higher risk of hypertension. 71 A study has shown an association of the 825T allele with hypertension in Whites. 72 This polymorphism is also associated with Na-sensitive form of hypertension. 73 Therefore, thiazide diuretics evoke increased effect on 825T allele carriers.
73 A large-scale association study in Japanese individuals by Izawa et al 2 found that C825T polymorphism in the G protein b 3 subunit gene was significantly associated with hypertension in men.
A recent study reported a significant difference of T393C polymorphism of the Gsa gene (GNAS1) between White hypertensive and controls. 74 However, another study on the Japanese population showed a marginal significant difference in the frequency of this polymorphism between hypertensives and controls. 75 Recent studies on RGS2 gene in mice showed that mutant mice deficient in RGS2 gene had higher mean arterial pressure than the wild mice. 75 Noradrenergic system (Table 3) Three polymorphisms (Arg16Gly, Glu27Gln and Thr164Ile) have been studied in the b 2 -receptor gene. Results from different ethnic groups are controversial and suggest further detailed studies on the mechanisms by which these polymorphisms might affect blood pressure variations. An association was found between 16Gly, 27Glu/Gln and 164Ilu with hypertension in a study on normal twins. 76 A genome-wide linkage analyses found a similar association between 16Gly and 27Glu/Gln with hypertension. 77 However, a study in Japanese population concluded that these polymorphisms are not associated with hypertension in this population. 78 Haplotype analyses of these polymorphisms did not find a significant association with essential hypertension. 79 It was observed that b 2 -receptor gene locus was associated with blood pressure in normotensive European subjects, but not the hypertensive subjects. 79 The clinical implication of these variants needs to be further studied. 80 Ser49Gly and Arg389Gly polymorphisms have been detected in the b1-receptor gene. The Arg389 variant was associated with increased risk of hypertension. 81 It was also shown that carriers of this variant have greater response to b blockers. 82 Genetic variations in dopamine receptor gene and a1b-adrenoceptor gene may influence interindividual variation in blood pressure. 83 Ion channels (Table 4 ) Studies on Liddle's syndrome (see above) indicated ENaC as a logical candidate gene for severe hypertension. In Black individuals, the T594M mutation of the b subunit of this gene increases the risk of hypertension. 40 However, this gene has a little influence on blood pressure in Japanese. 84 A sibling-pair analysis of White individuals indicated a linkage between systolic blood pressure and microsatellite markers on chromosome 16p12.3, a region close to the gene coding for the b and g subunits of ENaC gene. 85 Genes coding for amiloride-sensitive sodium channels (SCNN1A, SCNN1B and SCNN1G) have also been studied. It was shown that SCNN1A G2139 allele increases the risk of hypertension. Sib-pair linkage analysis showed that the SCNN1b and SCNN1G are implicated in the pathogenesis of systolic blood pressure. 85 Immune system and inflammation (Table 5 ) Several elements of the immune system have been studied for their possible role in the aetiology of hypertension. Only a few studies identified a significant association between these elements and hypertension. For example, studies on the linkage between nitric oxide synthase (NOS3) gene polymorphisms and hypertension have been controversial. No significant association was found between G11T mutation (NOS3) gene with hypertension in Polish people. 86 However, the CA repeat polymorphism of the NOS3 gene is associated with essential hypertension without left ventricular hypertrophy, and may be a genetic marker of essential hypertension in Japanese subjects. 87 This was supported by another study, which reported that the Glu298Asp variant might be a genetic susceptibility factor for hypertension in northern Japan. 88 A recent study found a significant interaction between a polymorphism in NOS3 gene and physical activity level on systolic blood pressure. 89 It was suggested that a repeat polymorphism of the human prostacyclin synthase gene seems to be a risk factor for systolic hypertension in the Japanese population. 90 However, no association was found between prostacyclin synthase gene polymorphism and essential hypertension in this population. 91 A recent study reported an association between a novel splicing mutation in this gene with hypertension. 91 It was also shown that IL-6 gene has a minimal role in the aetiology of hypertension in Japanese women. 92 Another study found that G174C polymorphism in this gene is not a marker for essential hypertension in a sample of elderly Italian subjects. 93 A recent study demonstrated an association between the IL-6 promoter polymorphism À174G/ C and high blood pressure in haemodialysis patients, especially those with diabetes. 94 A study in Japanese population indicated that TGF-b 1 gene could be a candidate susceptibility locus for hypertension in Japanese women. 95 A recent review indicated that in essential hypertensive patients, TGF-b 1 protein as well as TGF-b 1 mRNA levels are hyperexpressed, and that the Arg 25 polymorphism in the TGF-b 1 gene is associated with higher blood pressure. 96 Several studies showed that endothelin-1 gene variants are associated with hypertension in overweight subjects. [97] [98] [99] Significant association was found between G238A polymorphism in tumor necrosis factor a gene and hypertension in Japanese women. 2 Other gene associations (Tables 6 and 7 ) Numerous other candidate genes have been studied (see table) . Sometimes, the results were controversial and difficult to draw conclusions out of them.
Conclusion
Harrap 100 stated, 'Genetics might never contribute to the diagnosis of common diseases simply because of the underlying complexities of these conditions. But that does not diminish the far greater potential of genetics for prevention and treatment.' Hypertension is characterized by large interpatient variability in response to drugs. This observation may indicate the significance of applying genetic information in managing this disease as has been pleasingly suggested by Harrap. 100 For example, thiazide diuretics tend to be more effective at lowering blood pressure among salt-sensitive patients. 73 Hence, it was suggested that a-adducin (Gly460Trp) and Gprotein b3 subunit gene polymorphisms may identify hypertensive patients likely to benefit from their use. 72, 101 Similarly, a study in Greek hypertensive patients treated with fosinopril (20 mg/day for 6 months) showed that reduction in systolic and diastolic blood pressure was significantly greater in patients with ACE D/D genotype than the I/D and I/I genotypes. 102 In contrast, among Japanese patients treated with imidapril (5 mg/day for 6 weeks), diastolic blood pressure tended to decrease more in I/I genotype than for other genotypes. 103 In addition, the I/I genotype has also been associated with increased susceptibility to development of cough during ACE inhibitor therapy. 82 These reports demonstrate that various patient populations may not, although they may all have hypertension, be eligible for the same drug treatment. It is expected that by identifying genetic variations that contribute to the variability among hypertensive patients it may become possible, at least for selected groups of patients, to tailor antihypertensive drug therapy according to genetic profile. In turn, a more effective and less costing management of the disease is anticipated. Also, this intervention may lead to optimization of blood pressure control and avoidance of drug side effects and might help in identifying novel targets for drug action, which could be more effective and cheaper to develop.
Employing genetic information in the management of hypertension has an opportunity not only to reduce morbidity and mortality of the disease but also it may lead to introduction of prophylactic measures with the potential to 'prevent' and 'cure' this major health risk. This startling potential stems out of the observation that in animal studies a 4-week period of ACE inhibitor treatment in young spontaneously hypertensive rats was sufficient to reduce the full expression of genetic hypertension and cardiovascular hypertrophy. 104 Nevertheless, the optimistic view of pharmacogenomics impact on hypertension pharmacotherapy also goes together with a number of challenges that are anticipated when interpreting the genetic collected data will be attempted. These challenges may be listed as follows:
The Task: There are estimated 15 000-30 000 genes that are expressed in any cell of the cardiovascular system. 105 The number of genes that is dealt with, at present, probably represents only a fraction of the relevant biological cascade in hypertension. The merit of genetic information may not be demonstrated prior to investing functionally fully the role of these genes in blood pressure regulation. Multitasking of genes: The fact that only 35 000 genes (not 150 000 as has been predicted) that our body needs to do with, implies that our genes must be capable of 'multitasking' by having their component coding regions rearranged and recombined with subunits of other genes for transcription. 106 If this speculation were correct, it would mean that studying genetics of hypertension might be more complex than anticipated. Lack of reproducibility of genetic association studies: A considerable degree of nonreproducibility tinged most of the cited studies in this article. This could be due to many reasons such as:
Poor study design: Most genetic association analyses utilize case-control design and cohort design that which are prone to population stratification that may, inadvertently, lead to biased results. 107 Currently, it has been suggested that employing rigorous evidence-based approaches and studying only those polymorphisms that are likely to affect gene function and influence risk of the disease may overcome lack of the reproducibility problem. 5 Low statistical power: The current knowledge with regard to the nature of the genetic phenotypic effect is incomplete. Thus, the statistical power to detect it is unknown, and therefore, assigning a point of significance is intricate. This sheer lack of power could be the results of small sample size of the study. Population heterogeneity is another reason for low statistical power. This is because it can lead to type I and type II errors. In addition, identifying those individuals with the appropriate ethnicity as well as the environmental load that acts as a control to the study population still remains a challenge. Also, large variation of genes in a population may hinder the design and interpretation of disease-association studies.
Therefore, larger studies with family-base design are needed to avoid these problems. Another approach to increase the power of the study is to perform multiple genotyping, in which the frequencies of many polymorphisms and their haplotypes are analysed in cases and controls. 108 There are other factors, which make the replication of genetic association studies results difficult. These include gene-gene interactions, gene-environment interactions, laboratory errors, positive publication and reporting biases.
Genotype vs phenotype concordance: There are individuals carrying the genotype in question without manifesting the disease. The reason/s for such phenomenon need/s to be identified. Results from animal experiments: Animal studies led to variable genes and gene effects compared to human studies.
Finally, the reason behind the complexity of ascertaining an unequivocal link between genetics and hypertension is apparently multifactorial. The field has many limitations, but it has opportunities. An example is the growing interest in studying gene-gene interactions. Williams et al 3 studied the effects of interactions between alleles at four candidate loci and concluded that genetic interactions at multiple loci rather than variants of a single gene underlie the genetic basis of hypertension. Another study showed that interaction between three candidate genes contribute to the prevalence and incidence of hypertension in Caucasians. 109 The concept of gene-gene interaction may further extends to include identifying protective/suppressive genetic variants: there is a likelihood of having protecting (as well as suppressive) genetic variants in our genome. These genes may offset adverse event/s in the course of the disease. Identifying these variants is necessary to ascertain their contribution to preventing the manifestation or ameliorating the pathophysiology of the disease.
As a final point, although studying genetic variations to guide pharmacotherapy might not find association/link between genetic variations and disease aetiology/severity, these variations in the form of haplotyping may be used to stratify patients for better selection of drugs regardless of the underlying disease mechanism. 110 This approach might be complicated with the fact that the response to drugs may be also influenced by age and introduction of new drugs. 107 
